Common stock, par value $0.01 per share
- Symbol
- CERT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
Certara, Inc.
CERTNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 4, 2026, Certara, Inc. (the “Company”) announced the departure of Leif E. Pedersen from his role as the Company’s President, Chief Commercial Officer, effective as of August 1, 2026. The Company intends to retain Mr.…
Company context
Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.
Current securities
Recent company filings
- Regulation FD DisclosureAug 7, 2026
- 10-Q filingAug 4, 2026
- Results of Operations and Financial ConditionAug 4, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJun 17, 2026
- Submission of Matters to a Vote of Security HoldersMay 15, 2026
Registered securities in this filing
Certara, Inc. · 8-K · Filed 2026-08-04
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
August 4, 2026, Certara, Inc. (the “Company”) announced the departure of Leif E. Pedersen from his role as the Company’s
President, Chief Commercial Officer, effective as of August 1, 2026. The Company intends to retain Mr. Pedersen as an employee in a Senior
Advisor role assisting with transition matters until December 31, 2026, at which time his employment will be terminated without cause
and Mr. Pedersen will be entitled to severance benefits pursuant to the terms of his existing employment agreement with Certara USA, Inc.,
dated as of July 30, 2020, and the Company’s Executive Officer Severance Policy. Please refer to the description of the post-employment
payments and benefits included under the heading “Executive Compensation-Termination and Severance” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities
and Exchange Commission on April 3, 2026, which description is incorporated herein by reference.